logo
Urgent recall for fish sold in multiple states that could leave customers PARALYZED

Urgent recall for fish sold in multiple states that could leave customers PARALYZED

Daily Mail​a day ago

Fish sold in multiple states has been recalled over fears it could contain paralyzing bacteria.
P. East Trading Corp is recalling cases of herring that were distributed across general stores in New York, New Jersey and Connecticut.
The company, based in Bronx, New York, sent out the product in 18lb wooden boxes marked with the container code 'Lot 1 PRC5073'.
The recall was sparked after food safety inspectors found the fish measured more than 5in in length and were uneviscerated, meaning they had not had their internal organs removed.
This heightens the risk of the meat carrying bacteria that causes botulism, a rare food-borne pathogen that attacks the body's nerves.
It is more commonly found in internal organs, especially the intestines, of fish.
Botulism can lead to full-body paralysis, including in muscles needed to breathe, making it fatal in rare cases.
Consumers are warned not to consume the product even if it does not look or smell spoiled.
No illnesses have been reported in relation to the recall.
The FDA urges any customers with symptoms such as muscle weakness, dizziness, slurred speech, abdominal swelling, constipation, difficulty breathing, and paralysis to seek medical attention immediately.
The authorities note that the fish - which is a product of Canada, caught in the cold waters of the Atlantic, and manufactured by Sea Star Seafood Ltd - might be difficult to spot, as it was likely repackaged at the retail locations it was distributed to.
Retail packaging and coding will vary based on location of purchase but the FDA has released a full list of the stores it was sent to, which totals more than 75.
No major retailers are included in the list, which is mainly made up of independent stores.
Symptoms of foodborne botulism usually appear within 12 to 36 hours of consuming contaminated food, but the range can be from a few hours to several days.
Botulism is caused by a toxin released by the bacteria Clostridium botulinum, which is normally found in spores in soil, marine areas, and on the surface of foods like fruits, vegetables, and seafood.
Fermented foods like wine and low-acid foods such as most vegetables, meats, and fish, are the most likely culprits.
The bacteria make spores, which act like protective coatings and are usually harmless.
However, warm and wet tight spaces lacking oxygen - such as metal cans or plastic jars - can cause the bacteria to release toxins that attack the central nervous system.
Botulism targets the body's nerves and can lead to paralysis, including in the muscles needed to breathe.
This makes five to 10 percent of cases fatal.
Other symptoms include difficulty swallowing, muscle weakness, double vision, drooping eyelids, blurry vision, slurred speech, difficulty breathing, and trouble moving the eyes.
The CDC estimates there are just 200 cases of botulism in the US every year, and 25 are from food, making it rare.
Other causes include infections and, rarely, injecting too much botulinum toxin used in Botox.
Consumers are urged to contact P. East Trading Corp to learn how to dispose of affected products and determine steps like being reimbursed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US FDA puts on hold Rein Therapeutics' lung disease drug trial
US FDA puts on hold Rein Therapeutics' lung disease drug trial

Reuters

time4 hours ago

  • Reuters

US FDA puts on hold Rein Therapeutics' lung disease drug trial

June 12 (Reuters) - Rein Therapeutics (RNTX.O), opens new tab has paused patient enrollment and dosing in a mid-stage trial of its lung disease drug in the U.S. after the Food and Drug Administration placed a clinical hold, the drug developer said on Thursday. Shares of the company fell nearly 10% after the bell. The company was testing a drug named LTI-03 to treat patients with idiopathic pulmonary fibrosis (IPF). The disease causes scarring of the lungs that makes it harder for them to work properly. Rein said in a filing that it is actively working with the FDA to remove the clinical hold. The FDA and Rein did not immediately respond to Reuters' requests for comment on why the hold was placed. The drug was well-tolerated and safe in an early-stage study in patients with IPF, the company said in the filing. No drug-related serious adverse events have been reported in any studies treating patients with LTI-03, it added. Rein continues to study the drug and enroll patients in Australia and Europe.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store